GLB1 and GM1 gangliosidosis: These gene therapy results in patient cells emphasize the importance of carefully monitoring the ER system with straightforward methods when developing gene therapies and, in the case of GM1 gangliosidosis, titrating the extent and duration of GLB1 dosage to avoid accumulation of transcriptionally up-regulated β-gal in the ER.